Literature DB >> 23803083

Endostar combined with cisplatin inhibits tumor growth and lymphatic metastasis of lewis lung carcinoma xenografts in mice.

Xiao-Peng Dong1, Tian-Hui Xiao, Hong Dong, Ning Jiang, Xiao-Gang Zhao.   

Abstract

OBJECTIVE: To investigate the effects of endostar, a recombined humanized endostatin, plus cisplatin on the growth, lymphangiogenesis and lymphatic metastasis of the Lewis lung carcinoma (LLC) in mice.
METHODS: A tumor model were established in C57BL/6 mice by intravenious transplantation of LLC cells. Then the mice were randomized to receive administration with NS, endostar, cisplatin, or endostar plus cisplatin. After the mice were sacrificed, tumor multiplicity, tumor size and lymph node metastasis were assessed. Then the expression of vascular endothelial growth factor-c (VEGF-C) and podoplanin were determined by immunohistochemical staining.
RESULTS: Endostar plus cisplatin significantly suppressed tumor growth. lymphatic metastasis and prolonged survival time of the mice without obvious toxicity. The inhibition of lymphatic metastasis was associated with decreased microlymphatic vessel density (MLVD) and expression of VEGF-C.
CONCLUSIONS: Endostar combined with cisplatin was more effective to suppress tumor growth and lymphatic metastasis than either agent alone. Thus this may provide a rational alternative for lung carcinoma treatment.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23803083     DOI: 10.7314/apjcp.2013.14.5.3079

Source DB:  PubMed          Journal:  Asian Pac J Cancer Prev        ISSN: 1513-7368


  8 in total

1.  Effect of Endostar combined with angiopoietin-2 inhibitor on malignant pleural effusion in mice.

Authors:  Shen-Cun Fang; Hai-Tao Zhang; Hui-Di Hu; Cai-Ying Wang; Ying-Ming Zhang
Journal:  Med Oncol       Date:  2014-12-06       Impact factor: 3.064

Review 2.  Potential lymphangiogenesis therapies: Learning from current antiangiogenesis therapies-A review.

Authors:  Michael Yamakawa; Susan J Doh; Samuel M Santosa; Mario Montana; Ellen C Qin; Hyunjoon Kong; Kyu-Yeon Han; Charles Yu; Mark I Rosenblatt; Andrius Kazlauskas; Jin-Hong Chang; Dimitri T Azar
Journal:  Med Res Rev       Date:  2018-03-12       Impact factor: 12.944

3.  Preparation of endostatin-loaded chitosan nanoparticles and evaluation of the antitumor effect of such nanoparticles on the Lewis lung cancer model.

Authors:  Rui-Lin Ding; Fang Xie; Yue Hu; Shao-Zhi Fu; Jing-Bo Wu; Juan Fan; Wen-Feng He; Yu He; Ling-Lin Yang; Sheng Lin; Qing-Lian Wen
Journal:  Drug Deliv       Date:  2017-11       Impact factor: 6.419

4.  Downregulation of survivin expression exerts antitumoral effects on mouse breast cancer cells in vitro and in vivo.

Authors:  Wen-Hui Ma; Yong-Chao Liu; Mei-Lan Xue; Zheng Zheng; Yin-Lin Ge
Journal:  Oncol Lett       Date:  2015-11-05       Impact factor: 2.967

5.  Differential effects of recombinant human endostatin treatment on differentiated and undifferentiated blood vessels in Lewis lung cancer.

Authors:  Weijiang Fu; Jing Zhuo; Likuan Hu
Journal:  Oncol Lett       Date:  2016-11-30       Impact factor: 2.967

6.  Anti-tumor effect of a novel soluble recombinant human endostatin: administered as a single agent or in combination with chemotherapy agents in mouse tumor models.

Authors:  Zhihua Ren; Yanan Wang; Wenhong Jiang; Wei Dai; Yongping Jiang
Journal:  PLoS One       Date:  2014-09-17       Impact factor: 3.240

7.  A nanocomplex of C60 fullerene with cisplatin: design, characterization and toxicity.

Authors:  Svitlana Prylutska; Svitlana Politenkova; Kateryna Afanasieva; Volodymyr Korolovych; Kateryna Bogutska; Andriy Sivolob; Larysa Skivka; Maxim Evstigneev; Viktor Kostjukov; Yuriy Prylutskyy; Uwe Ritter
Journal:  Beilstein J Nanotechnol       Date:  2017-07-20       Impact factor: 3.649

8.  Evaluation of collagen derived antiangiogenic factors and matrix metalloproteinases in anterior lens epithelial cells of pediatric eyes with persistent fetal vasculature.

Authors:  Devarshi U Gajjar; Abhay R Vasavada; Priyanka Patel; Mamidipudi R Praveen; Sajani R Shah
Journal:  Indian J Ophthalmol       Date:  2019-10       Impact factor: 1.848

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.